Pfizer Inc. (ETR:PFE)
Germany
· Delayed Price · Currency is EUR 20.11
-0.18 (-0.86%)
May 9, 2025, 1:43 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Oncology | 15.82B |
Log In |
Log In |
Log In |
Log In |
| Oncology Growth | 21.68% |
Log In |
Log In |
Log In |
Log In |
| Business Innovation (Pfizer CentreOne) | 1.15B |
Log In |
Log In |
Log In |
Log In |
| Business Innovation (Pfizer CentreOne) Growth | -6.22% |
Log In |
Log In |
Log In |
Log In |
| Global Pharmaceuticals Business (Biopharma) | 61.24B |
Log In |
Log In |
Log In |
Log In |
| Global Pharmaceuticals Business (Biopharma) Growth | 12.02% |
Log In |
Log In |
Log In |
Log In |
| Primary Care | 28.62B |
Log In |
Log In |
Log In |
Log In |
| Primary Care Growth | 8.20% |
Log In |
Log In |
Log In |
Log In |
| Specialty Care | 16.80B |
Log In |
Log In |
Log In |
Log In |
| Specialty Care Growth | 10.40% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| United States Revenue | 37.55B |
Log In |
Log In |
Log In |
Log In |
| United States Revenue Growth | 29.72% |
Log In |
Log In |
Log In |
Log In |
| Developed Europe Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Developed Europe Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Developed Rest of World Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Developed Rest of World Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| International Revenue | 24.91B |
Log In |
Log In |
Log In |
Log In |
| International Revenue Growth | -7.72% |
Log In |
Log In |
Log In |
Log In |
| Developed Markets Revenue | 16.04B |
Log In |
Log In |
Log In |
Log In |
| Developed Markets Revenue Growth | -13.19% |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue (Post-FY2023 Reporting) | 8.88B |
Log In |
Log In |
Log In |
Log In |
| Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 4.12% |
Log In |
Log In |
Log In |
Log In |
| Global Pharmaceuticals Business (Biopharma) Earnings | 27.62B |
Log In |
Log In |
Log In |
Log In |
| Global Pharmaceuticals Business (Biopharma) Earnings Growth | -6.78% |
Log In |
Log In |
Log In |
Log In |
| Other Business Activities Earnings | -6.80B |
Log In |
Log In |
Log In |
Log In |
| Other Business Activities Earnings Growth | -29.25% |
Log In |
Log In |
Log In |
Log In |
| Prevnar Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Prevnar Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Xeljanz Revenue | 1.10B |
Log In |
Log In |
Log In |
Log In |
| Xeljanz Revenue Growth | -33.57% |
Log In |
Log In |
Log In |
Log In |
| Vaccines Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Vaccines Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Ibrance Revenue | 4.29B |
Log In |
Log In |
Log In |
Log In |
| Ibrance Revenue Growth | -8.02% |
Log In |
Log In |
Log In |
Log In |
| Internal Medicine Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Internal Medicine Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Inflammation & Immunology Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Inflammation & Immunology Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Rare Disease Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Rare Disease Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Eliquis Alliance Revenue and Direct Sales | 7.25B |
Log In |
Log In |
Log In |
Log In |
| Eliquis Alliance Revenue and Direct Sales Growth | 4.88% |
Log In |
Log In |
Log In |
Log In |
| Vyndaqel Family Revenue | 5.80B |
Log In |
Log In |
Log In |
Log In |
| Vyndaqel Family Revenue Growth | 53.76% |
Log In |
Log In |
Log In |
Log In |
| Hospital Revenue | - |
Log In |
Log In |
Log In |
Log In |
| Hospital Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
| Comirnaty Direct Sales and Alliance Revenue | 5.57B |
Log In |
Log In |
Log In |
Log In |
| Comirnaty Direct Sales and Alliance Revenue Growth | -34.60% |
Log In |
Log In |
Log In |
Log In |
| Paxlovid Revenue | 4.17B |
Log In |
Log In |
Log In |
Log In |
| Paxlovid Revenue Growth | -652.58% |
Log In |
Log In |
Log In |
Log In |
| Prevnar Family Revenue | 6.38B |
Log In |
Log In |
Log In |
Log In |
| Prevnar Family Revenue Growth | -3.17% |
Log In |
Log In |
Log In |
Log In |
| Nurtec ODT/Vydura Revenue | 1.33B |
Log In |
Log In |
Log In |
Log In |
| Nurtec ODT/Vydura Revenue Growth | 41.81% |
Log In |
Log In |
Log In |
Log In |
| Abrysvo Revenue | 741.00M |
Log In |
Log In |
Log In |
Log In |
| Abrysvo Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |